Sign In
Buy XFOR
$3.97
-0.0700 (-1.73%)
At Close: Jun 03, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 01'st Jun 2026
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
07:00am, Wednesday, 27'th May 2026
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will prese
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
10:55am, Wednesday, 20'th May 2026
X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 18'th May 2026
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
09:31am, Wednesday, 06'th May 2026
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to earnings of $0.04 per share a year ago.
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:15am, Wednesday, 06'th May 2026
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authoriz
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April 29,
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 01'st Apr 2026
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
09:26am, Tuesday, 17'th Mar 2026
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $6.01 per share a year ago.
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
07:15am, Tuesday, 17'th Mar 2026
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
11:15am, Monday, 09'th Mar 2026
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 cli
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
07:00am, Wednesday, 04'th Mar 2026
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
10:04am, Tuesday, 03'rd Mar 2026
X4 Pharmaceuticals (XFOR) is rated BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. XFOR's primary value lies in its 4WARD Phase 3 trial
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 02'nd Mar 2026
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on Febru
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
07:00am, Friday, 27'th Feb 2026
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of p
